Overview

Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children

Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Proton pump inhibitors are administered to children as off-label use in Japan. The purpose of this study is to evaluate the effects of CYP2C19 genotypes on pharmacokinetic /pharmacodynamic profiles of PPI in children. The results will provide the beneficial information for the individualized medicine of PPI in children.
Phase:
Phase 4
Details
Lead Sponsor:
Osaka University
Treatments:
Dexlansoprazole
Lansoprazole
Proton Pump Inhibitors